Braidwell LP Increases Stock Position in Kymera Therapeutics, Inc. $KYMR

Braidwell LP increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 12.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 378,163 shares of the company’s stock after buying an additional 40,604 shares during the period. Kymera Therapeutics accounts for 1.6% of Braidwell LP’s investment portfolio, making the stock its 19th biggest position. Braidwell LP’s holdings in Kymera Therapeutics were worth $43,364,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the period. GAMMA Investing LLC raised its stake in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Kymera Therapeutics during the 4th quarter worth about $63,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on KYMR shares. Canaccord Genuity Group lifted their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th. Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price objective for the company. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. B. Riley Financial upped their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $128.70.

Kymera Therapeutics Stock Down 0.4%

Shares of NASDAQ KYMR opened at $118.63 on Thursday. The firm has a market capitalization of $9.86 billion, a P/E ratio of -36.61 and a beta of 1.96. The stock’s 50-day simple moving average is $113.96 and its two-hundred day simple moving average is $94.49. Kymera Therapeutics, Inc. has a twelve month low of $40.10 and a twelve month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same quarter last year, the company posted ($0.95) EPS. The company’s revenue for the quarter was up 465.2% on a year-over-year basis. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 31,283 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the transaction, the director owned 461,794 shares of the company’s stock, valued at $50,557,207.12. This represents a 6.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 over the last three months. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.